FDA's proposal to introduce user fees attracts low-key response from Congress
This article was originally published in Clinica
There was surprisingly little reaction from Congress last week to the US FDA's proposal to impose $7 million in user fees on the medical device industry in fiscal 2000. Indeed, only two members of the House Appropriations subcommittee responsible for the FDA's budget even raised the issue at the agency's annual budget hearing.
You may also be interested in...
Can shaving ever be “friction free”? Not according to Procter & Gamble, which challenged in a complaint to the UK Advertising Standards Authority a claim made by a British cosmetics firm FFS that it provided a “friction free” shaving experience for women via its subscription razor service.
Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.